Trouble reading this e-mail? View it in your browser.

EFPIA
Newsletter
16 June 2016
Header
Header image
Highlight of the week

Highlight of the week

EFPIA Annual Report for 2015
16 June 2016

Welcome to EFPIA’s Annual Report for 2015. The report covers the major issues that have impacted the industry over the past year and offers further insight into potential developments in and around our sector in the year ahead. It is divided into easily accessible sections and is accompanied by informative facts and statistics concerning the industry.

Read more

News

News

European CSRs Must Go Beyond the Realms of Cost Containment and Fiscal Sustainability
14 June 2016

EFPIA welcomes the proposals for Country Specific Recommendations (CSRs) published by the European Commission as part of the European Semester 2016. The CSRs for 2016 [...] Read more

News

EBE, the European Biopharmaceutical Trade Association, Unveils Its Leadership 2016-2018
16 June 2016

The European Biopharmaceutical Enterprises, EBE, is pleased to announce its Board of Directors for the term 2016-2018, following the decisions taken at the EBE and [...] Read more

From our blog

From our blog

Evolution – Not Revolution
16 June 2016 by Richard Bergström

This week Reuters news agency published a story entitled: “Industry weighs radical shake up of European Drug pricing”. It was based on a leaked discussion paper, produced by an EFPIA working group with members drawn from right across the EFPIA membership.

Read more

From our blog

Perfecting access through embedded sustainability, pooling resources and consolidating expertise (Guest blog)
16 June 2016 by Anthony Gitau

I remember when I first really began to understand the necessity of access to medicines in my country, Kenya.

Read more

From our blog

From Mouthwash to Medicine: Unexpected Innovations (Guest blog)
16 June 2016 by Jon Pender

When searching for a potential medicine, you don’t expect to find inspiration in your bathroom cabinet. That, though, is precisely what happened for one of our scientists.

Read more

From our blog

Voluntary Patent Pooling: Encouraging Rapid Scale-Up of Medicines for Resource-Limited Countries (Guest blog)
16 June 2016 by Greg Perry

At last month’s World Health Assembly, discussions returned to some familiar themes around financing development and health priorities over the long term. The 2015 United Nations Sustainable Development Goals (SDGs) come with a price tag of three to five trillion dollars a year, with ambitious health indicators ranging from ending AIDS to providing universal health coverage. To meet these targets, new funding mechanisms, creative ways to partner and innovative approaches to pooling resources are imperative.

Read more

From our blog

Transparency Is Key When Collaborating With Healthcare Professionals (Guest blog)
16 June 2016 by Andrew Hotchkiss

Working with healthcare professionals is critical if we are to deliver the innovation necessary to create medicines that meet real patient needs. Working with healthcare professionals makes for better medicines and ultimately benefits patients.

Read more

From our blog

Tackling TB through Partnership (Guest blog)
16 June 2016 by Evan Lee

Published recently, the “Review on Antimicrobial Resistance” cited multidrug-resistant tuberculosis (MDR-TB) as a “cornerstone of the global AMR challenge”. It was estimated that, of the 10 million potential annual deaths that could be associated with drug-resistance by 2050, about 25% would be from multidrug-resistant tuberculosis (MDR-TB).

Read more

Videos

Video

Powering Growth in Europe

For every Euro of direct value added by the pharmaceutical industry, more than 1.3 additional Euros are generated for the whole European economy.

View video

Documents

From our blog

The Pharmaceutical Industry in Figures
16 June 2016 (Publications)

Download the 2016 edition of our annual [...] Read more

What we are reading

What we are reading

Would Brexit compromise the future of UK science?
16 June 2016 (BBC )

Leading scientists have been particularly vocal in arguing against the UK leaving the European Union. But how would Brexit really affect UK science?

Read more

Sessions Views

EFPIA’s Annual Meeting: From Innovation to Outcomes

EFPIA’s Annual Meeting: From Innovation to Outcomes
16 June 2016

View album

About EFPIA updates
Unsubscribe to be removed from this mailing list | Update your subscription

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 34 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)
Tel: +32 (0)2 626 25 55
E-mail: communications@efpia.eu
Follow EFPIA
Twitter LinkedIn Youtube Google + Pinterest E-mail